Research graph
References from Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global survey. Local targets link to admitted publications; unresolved targets remain external evidence.
Intermediate and high‐risk non‐muscle‐invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
10.3389/fonc.2023.1170124 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
The global burden of urinary bladder cancer: an update
10.1007/s00345-019-02984-4 · 2020 · External reference
Estimated costs and long‐term outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer treated with bacillus Calmette‐Guerin in the veterans affairs health system
10.1001/jamanetworkopen.2021.3800 · 2021 · External reference
A systematic review of novel intravesical approaches for the treatment of patients with non–muscle‐invasive bladder cancer
10.1016/j.eururo.2025.02.010 · 2025 · External reference
European Association of Urology (EAU) prognostic factor risk groups for non–muscle‐invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel
10.1016/j.eururo.2020.12.033 · 2021 · External reference
Contemporary treatment of NMIBC‐is it time to move on from BCG?
10.3390/jcm13144112 · 2024 · External reference
The management of BCG failure in non‐muscle‐invasive bladder cancer: an update
10.5489/cuaj.1196 · 2009 · External reference
Unresolved reference
2025 · External reference
Treatment options in non‐muscle‐invasive bladder cancer after BCG failure
10.4103/0970-1591.166475 · 2015 · External reference
Canadian Urological Association guideline on the management of non‐muscle‐invasive bladder cancer – abridged version
10.5489/cuaj.7487 · 2021 · External reference
Unresolved reference
External reference
Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow‐up
10.1016/j.annonc.2021.11.012 · 2022 · External reference
Clinical practice guideline on bladder cancer (part III)
10.1002/uro2.35 · 2024 · External reference
Emerging treatments for bacillus Calmette‐Guerin‐unresponsive non‐muscle‐invasive bladder cancer
10.4111/icu.20200602 · 2021 · External reference
Patient preferences for treatment of bacillus Calmette‐Guerin‐unresponsive non‐muscle‐invasive bladder cancer: a cross‐country choice experiment
10.1016/j.euros.2022.12.016 · 2023 · External reference
Radical cystectomy for bladder cancer in sub‐Saharan Africa: techniques, challenges, and survival outcomes: a comprehensive review
10.1186/s12893-025-02887-9 · 2025 · External reference
10.1200/jco.2024.42.4_suppl.701
10.1200/jco.2024.42.4_suppl.701 · 2024 · External reference
Real‐world physician and patient behaviour across countries: disease‐specific Programmes – a means to understand
10.1185/03007990802457040 · 2008 · External reference
Diagnosis and treatment of non‐muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment
10.1097/ju.0000000000003846 · 2024 · External reference
Clinical practice guidelines for bladder cancer 2019 edition by the Japanese Urological Association: revision working position paper
10.1111/iju.14210 · 2020 · External reference
French ccAFU guidelines – update 2020–2022: bladder cancer
2020 · External reference
New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification
10.1111/j.1464-410x.2010.09324.x · 2010 · External reference
Long‐term cancer‐specific survival in patients with high‐risk, non‐muscle‐invasive bladder cancer and tumour progression: a systematic review
10.1016/j.eururo.2011.05.045 · 2011 · External reference
Quantifying the overall survival benefit with early radical cystectomy for patients with histologically confirmed T1 non‐muscle‐invasive bladder cancer
10.1016/j.clgc.2020.03.013 · 2020 · External reference
Can we lower the rates of cystectomy complications by modifying risk factors? A review of the literature
2022 · External reference
Treatment outcomes of high‐risk non‐muscle invasive bladder cancer (HR‐NMIBC) in real‐world evidence (RWE) studies: systematic literature review (SLR)
10.2147/ceor.s341896 · 2022 · External reference
Systematic review of factors associated with the utilization of radical cystectomy for bladder cancer
10.1016/j.euo.2018.07.006 · 2019 · External reference
Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy
10.1016/s1078-1439(03)00144-3 · 2004 · External reference
Novel delivery systems and pharmacotherapeutic approaches for the treatment of non–muscle‐invasive bladder cancer
10.1016/j.euo.2024.05.012 · 2024 · External reference
New treatment options for non‐muscle‐invasive bladder cancer
10.1200/edbk-25-471942 · 2025 · External reference
